We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 9/1/2022

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

story of the week

Journal Scan / Research · June 30, 2022

Nivolumab Plus Cabozantinib vs Sunitinib in the First-Line Treatment for Advanced RCC

The Lancet Oncology

 

TAKE-HOME MESSAGE

abstract

This abstract is available on the publisher's site.

Access this abstract now   Full Text Available for ClinicalKey Subscribers

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
Lancet Oncol 2022 Jun 07;[EPub Ahead of Print], RJ Motzer, T Powles, M Burotto, B Escudier, MT Bourlon, AY Shah, C Suárez, A Hamzaj, C Porta, CM Hocking, ER Kessler, H Gurney, Y Tomita, J Bedke, J Zhang, B Simsek, C Scheffold, AB Apolo, TK Choueiri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.


Further Reading